Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

OPTIMUM LABS INC

NPI: 1902123052 · NEW BEDFORD, MA 02745 · Clinical Medical Laboratory · NPI assigned 04/29/2010

$5.79M
Total Medicaid Paid
132,372
Total Claims
28,472
Beneficiaries
3
Codes Billed
2018-01
First Month
2021-09
Last Month

Provider Details

Authorized OfficialOWENS, WILLIAM (OWNER)
NPI Enumeration Date04/29/2010

Related Entities

Other providers sharing the same authorized official: OWENS, WILLIAM

ProviderCityStateTotal Paid
PALMETTO BONE AND JOINT NEWBERRY SC $236K
TODD'S PHARMACY INC ELIZABETH CITY NC $240.50

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 50,778 $2.25M
2019 31,713 $1.44M
2020 27,748 $1.15M
2021 22,133 $958K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 98,004 20,448 $4.19M
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 33,958 7,800 $1.58M
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 410 224 $27K